English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A rapid, precise and accurate reverse phase high performance liquid chromatographic method have been developed for the validated of DOXOFYLLINE AND MONTELUKAS SODIUM, in its original form as well as in pharmaceutical dosage form. Chromatography conditionswas carried out on a Phenomenex HYPERSIL ODS, RP18,250×4.6mm ID, column using a mixture of Ammonium acetate: Methanol (60:40) as the mobile phase at a flow rate of 1.0ml/min, the detection was carried out at 219nm. The retention time of the DOXOFYLLINE AND MONTE LUKAS SODIUM was 2.34, 4.81 ±0.02min respectively. The method produce linearity responses in the range of 1.53.5mg/ml of DOXOFYLLINE and 60-140mg/ml of MONTELUKAS SODIUM. The limit of detection of Montelukast & Doxofylline 0.021 μg/ml & area 2.61 and 1.54 μg/ml & area 104.45 respectively. The limit of quantitation of Montelukast was found to be 0.06μg/ml & area 7.91 whereas for Doxofylline was 4.68 μg/ml & area 316.51. The percentage of recovery of Montelukast and Doxofylline was found to be 99.96% and 100.85% respectively. The method is useful for the quality and quality control of bulk and pharmaceutical formulations.

Analytical Method Development and Validation for Simultaneous Estimation of Doxofylline and Montelukast Sodium in Bulk and Pharmaceutical Dosage Form